TRAXENS
28.5.2019 09:02:10 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, announces today that its patented cargo tracking IoT system will be used on CFL multimodal’s connected freight wagons throughout the European corridor and the New Silk Road to China.
Traxens and CFL multimodal (CFL) started their co-operation with a pilot project at the end of 2018, when CFL fitted Traxens Box devices on flat wagons travelling between European destinations. As this initial trial was successful, it was extended earlier this year to over 20 wagons delivering cargo to more distant European destinations. In April 2019 Traxens’ rail freight telematics technology was then tested on wagons travelling to China.
As part of it digitalization strategy, CFL aims to streamline train preparation operations through automation, including digital brake testing. Traxens’ Digital Freight Train® solutions can consolidate, secure and accelerate brake safety testing. This testing system can bring a number of benefits:
- Thirty minutes saved on standard reallocation processes to improve robustness or optimize loading
- Continuous monitoring of the brake system after departure, with real-time alerts for the train driver to prevent a flat wheel
- Improved safety and working conditions for shunting and ground operators who perform brake tests
- Can be used solely by the train driver instead of two agents — reducing operating costs and improving agility and quality of the whole system
- In the longer term, it will allow the interconnection of operators systems to improve interoperability and international trade, leading to better global efficiency of rail freight
Traxens’ solution provides comprehensive, precise and timely data about cargo by tracking wagons in transit anywhere in the world. Traxens’ technology brings improved efficiency and security, greater transparency and enhanced asset utilization thanks to improved wagons and goods tracking, geolocalisation and mileage monitoring.
The Traxens Box is straightforward to install within a few minutes whether on the customers’ sites, at railway terminals or workshops; it can be adapted to any type of wagon.
“As an outcome of our joint pilot project, we are delighted that CFL multimodal decided to extend its use of our bespoke IoT technology in its rail freight operations to China,” said Florence Delalande, rail business unit director at Traxens. “This shows the potential of our technology for all rail and intermodal freight businesses, as the shipping industry shifts towards a digital future.”
“Traxens’ rail freight solution helps our operations by enabling the monitoring of assets and their surroundings, which significantly improves operational efficiency,” said Marc Valette, innovation director at CFL multimodal. “The technology used by Traxens, enabling the local interconnection of different devices without wiring, opens up new opportunities in train condition and composition monitoring. This is a huge opportunity to improve operations and service effectiveness in rail. It will allow the connection of different elements of the train ecosystem in the future, providing transparent and accurate information, improving the quality of service and information delivered to clients.”
This agreement with CFL Multimodal is the latest development for Traxens in the rail sector. Traxens has already started cooperations with other key players in the industry, such as SNCF (the French national railway company). In cooperation with SNCF Logistics, Traxens developed the Digital Freight Train and its high value-added services for the benefit of the entire railway system, by turning conventional wagons into intelligent wagons in record time. It features geolocation, arrival notifications, consignment transport conditions and status monitoring, digital assistance for wagon management, predictive maintenance and more. Traxens offers a whole range of services for a safer, more modern, eco-friendly and more efficient freight railway system.
This year Traxens has already won several innovation awards for its Digital Freight Train project.
About CFL Multimodal
CFL multimodal is a logistics service
provider, covering the entire logistics chain. With 12 companies in six
European countries, CFL multimodal and its sister company CFL cargo
offer a broad and customised service portfolio: combined and
conventional rail freight, wagon maintenance and repairs, customs
clearance, as well as forwarding and logistics services. In Luxembourg,
the activities of CFL multimodal are organised around the intermodal
terminal of Bettembourg-Dudelange on the Eurohub South Logistics Park.
Located on the Rail Freight Corridor 2 (North Sea-Mediterranean) and at
the crossroads of major transport routes, the terminal is ideally
positioned as an international hub for the consolidation of multimodal
transport flows across Europe and beyond. With a total yearly capacity
of 600,000 units and equipped with the latest technology in terms of
security and surveillance, the intermodal terminal is connected by
combined train shuttles to the main ports and industrial regions.
www.cfl-mm.lu
ABOUT TRAXENS
Traxens generates, collects, consolidates,
enriches and transforms logistics asset data into actionable insight for
its clients in the maritime, rail and supply chain industries.
The
company’s breakthrough Internet-of-Big-Things technology provides
comprehensive, real-time information for managing logistics assets
anywhere in the world. Traxens’ solutions digitally transform
multi-modal supply chains, enabling customers to reduce costs, optimize
investments, comply with environmental regulations and deliver premium
services to their customers. Traxens’ IoT solution received the Frost &
Sullivan’s Technology Leadership Award in 2019.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005138/en/
Contact:
PRESS: Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
